Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial [Gastrointestinal Cancer]

Conclusion
Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma. There were clear differences in the effect of lapatinib depending on region and age. Future studies could examine this correlation.

Source: Journal of Clinical Oncology - February 2, 2016 Category: Cancer & Oncology Authors: Hecht, Bang, Qin, Chung, Xu, Park, Jeziorski, Shparyk, Hoff, Sobrero, Salman, Li, Protsenko, Wainberg, Buyse, Afenjar, Houe, Garcia, Kaneko, Huang, Khan-Wasti, Santillana, Press, Slamon Tags: Clinical Trials, Chemotherapy Gastrointestinal Cancer Source Type: research